Annuncio • Jun 19
BioPharma Credit PLC Declares Interim Dividend for Quarter Ending 30 June 2026, Payable on 31 July 2026 BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 30 June 2026 of 1.75 cents per share, payable on 31 July 2026 to ordinary shareholders on the register as at 3 July 2026. The ex-dividend date will be 2 July 2026. The Company aims to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from its investments in the life sciences industry. The Company currently pays, and continues to target, a 7-cent base annual dividend per ordinary share in four quarterly payments of 1.75 cents per share. Typically, these are supplemented by excess income in the form of special dividend distributions in Fourth Quarter and in some years, Third Quarter and Q4, where the Board determines that it is appropriate and able to do so (noting the requirement to pay out substantially all income to maintain the Company's investment trust status). Annuncio • May 06
BioPharma Credit PLC, Annual General Meeting, Jun 17, 2026 BioPharma Credit PLC, Annual General Meeting, Jun 17, 2026. Location: the offices of herbert smith freehills llp, exchange house, primrose street, ec2a 2eg, london United Kingdom Annuncio • Apr 24
BioPharma Credit PLC Declares Interim Dividend in Respect of the Quarterly Financial Period Ending 31 March 2026, Payable on 29 May 2026 BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 31 March 2026 of 1.75 cents per share, payable on 29 May 2026 to ordinary shareholders on the register as at 1 May 2026. The ex-dividend date will be 30 April 2026. The Company's investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from its investments in the life sciences industry. The Company currently pays, and continues to target, a 7-cent base annual dividend per ordinary share in four quarterly payments of 1.75 cents per share. Typically, these have been supplemented by excess income in the form of special dividend distributions in Fourth Quarter and in some years, Third Quarter and Q4, where the Board determines that it is appropriate and able to do so (noting the requirement to pay out substantially all income to maintain the Company's investment trust status). Annuncio • Feb 03
BioPharma Credit PLC to Report Fiscal Year 2025 Results on Mar 24, 2026 BioPharma Credit PLC announced that they will report fiscal year 2025 results on Mar 24, 2026 Annuncio • Aug 26
BioPharma Credit PLC to Report Q2, 2025 Results on Sep 22, 2025 BioPharma Credit PLC announced that they will report Q2, 2025 results on Sep 22, 2025 Annuncio • Aug 21
BioPharma Credit PLC (LSE:BPCR) commences an Equity Buyback Plan for 169,286,233 shares, representing 14.99% of its issued share capital, under the authorization approved on June 9, 2025. BioPharma Credit PLC (LSE:BPCR) commences share repurchases on August 20, 2025, under the program mandated by the shareholders in the Annual General Meeting held on June 9, 2025. As per the mandate, the company is authorized to repurchase up to 169,286,233 shares, representing 14.99% of issued share capital. The minimum price which may be paid per any ordinary share is US$0.01 and The maximum price which may be paid for any ordinary share is the higher of 5% above the average of the mid-market values of such ordinary share for the five business days before the purchase is made, or the higher of the price of the last independent trade and the highest current independent bid for such ordinary share. The shares repurchased pursuant to the buyback will be cancelled or held in treasury. The repurchase program is valid till next Annual General Meeting to be held in 2026. As of May 6, 2025, the company had 1,373,932,067 shares in issue of which 244,604,289 shares were in treasury. Annuncio • Jul 31
BioPharma Credit PLC Appoints Nigel Reynolds as Non-Executive Director, Effective 1 January 2026 BioPharma Credit PLC announced the appointment of Nigel Reynolds as a non-executive Director with effect from 1 January 2026, following his retirement from PwC on 31 December 2025. Mr. Reynolds will, after a transition period, take over as chair of the Company's Audit and Risk committee. Mr. Reynolds has 34 years of accounting and finance experience advising both listed and private companies. He has been a partner at PwC for 20 years specialising in audit, transaction services and capital markets work. During his time at PwC, he led its London Assurance practice for 5 years, led the private equity portfolio company practice and was the relationship partner for various UK listed and international companies including companies in healthcare and investment trusts. Over his career he has also advised companies on strategy, M&A, internal audit and tax and has overseen technology, sustainability, and other large projects for PwC clients. Annuncio • Jun 19
BioPharma Credit PLC Declares Interim Dividend in Respect of the Quarterly Financial Period Ending 30 June 2025, Payable on 31 July 2025 BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 30 June 2025 of 1.75 cents per share, payable on 31 July 2025 to ordinary shareholders on the register as at 27 June 2025. The ex-dividend date will be 26 June 2025. Annuncio • Feb 20
BioPharma Credit PLC to Report Fiscal Year 2024 Results on Mar 25, 2025 BioPharma Credit PLC announced that they will report fiscal year 2024 results on Mar 25, 2025 Annuncio • Aug 16
BioPharma Credit PLC to Report First Half, 2024 Results on Sep 24, 2024 BioPharma Credit PLC announced that they will report first half, 2024 results on Sep 24, 2024 Annuncio • Jul 31
BioPharma Credit PLC (LSE:BPCR) commences an Equity Buyback Plan for 185,505,277 shares, representing 14.99% of its issued share capital, under the authorization approved on June 12, 2024. BioPharma Credit PLC (LSE:BPCR) commences share repurchases on July 30, 2024, under the program mandated by the shareholders in the Annual General Meeting held on June 12, 2024. As per the mandate, the company is authorized to repurchase up to 185,505,277 shares, representing 14.99% of issued share capital. The minimum price which may be paid per any ordinary share is US$0.01 and The maximum price which may be paid for any ordinary share is the higher of 5% above the average of the mid-market values of such ordinary share for the five business days before the purchase is made, or the higher of the price of the last independent trade and the highest current independent bid for such ordinary share. The shares repurchased pursuant to the buyback will be cancelled or held in treasury. The repurchase program is valid till next Annual General Meeting to be held in 2025. As of April 15, 2024, the company had 1,237,526,871 shares in issue of which 136,405,196 shares were in treasury. Annuncio • Jun 22
BioPharma Credit PLC Declares Interim Dividend in Respect of the Financial Period Ending 30 June 2024, Payable on 31 July 2024 BioPharma Credit PLC declared an interim dividend in respect of the financial period ending 30 June 2024 of $0.0175 per ordinary share, payable on 31 July 2024 to ordinary shareholders on the register as at 5 July 2024. The ex-dividend date will be 4 July 2024. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company. The Company is currently paying and continues to target a 7-cent annual dividend per ordinary share. Annuncio • Mar 27
BioPharma Credit PLC, Annual General Meeting, Jun 12, 2024 BioPharma Credit PLC, Annual General Meeting, Jun 12, 2024. Annuncio • Mar 22
Biopharma Credit plc Declares Interim Dividend in Respect of the Financial Period Ending 31 March 2024, Payable on 30 April 2024 BioPharma Credit PLC declared an interim dividend in respect of the financial period ending 31 March 2024 of $0.0175 per ordinary share, payable on 30 April 2024 to ordinary shareholders on the register as at 2 April 2024. The ex-dividend date will be 28 March 2024. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company. Annuncio • Feb 27
BioPharma Credit PLC to Report Fiscal Year 2023 Results on Mar 27, 2024 BioPharma Credit PLC announced that they will report fiscal year 2023 results on Mar 27, 2024 Annuncio • Sep 27
BioPharma Credit PLC Provides Dividend Guidance for the Full Year Ending December 31, 2023 BioPharma Credit PLC provided dividend guidance for the full year ending December 31, 2023. For the period, the company's target dividend of 7 cents per annum (December 31, 2022: 7 cents per annum). Annuncio • Aug 31
BioPharma Credit PLC to Report Q2, 2023 Results on Sep 27, 2023 BioPharma Credit PLC announced that they will report Q2, 2023 results on Sep 27, 2023 Annuncio • Aug 11
BioPharma Credit PLC Declares Interim Dividend in Respect of the Financial Period Ending 30 June 2023, Payable on 15 September 2023 BioPharma Credit PLC declared an interim dividend in respect of the financial period ending 30 June 2023 of $0.0175 per ordinary share, payable on 15 September 2023 to ordinary shareholders on the register as at 18 August 2023. The ex-dividend date will be 17 August 2023. 
